Acute and chronic effects of citalopram on cerebral glucose metabolism in geriatric depression.

OBJECTIVE In vivo studies of serotonin function have been limited by the lack of safe and selective pharmacologic agents and availability of suitable radiotracers. In the present study, the authors evaluated the cerebral metabolic effects of acute and continued administration of the selective serotonin reuptake inhibitor citalopram in patients with geriatric depression as a potential marker of serotonin dysfunction. METHODS Six patients with geriatric depression and five comparison subjects underwent two resting positron emission tomography (PET) studies, performed after administration of a placebo infusion (Day 1) and a citalopram infusion (40 mg, Day 2). The patients were re-scanned after 8 weeks of treatment with the oral medication. RESULTS The elderly comparison subjects demonstrated greater right-hemisphere cortical decreases than the patients. The depressed patients demonstrated greater left-hemisphere cortical decreases than comparison subjects. The depressed patients demonstrated greater increases in the right putamen and left occipital cortex. After 8 weeks of citalopram treatment, regional decreases and increases in metabolism were observed. CONCLUSION These findings suggest regional deficits and also compensatory responses in the acute metabolic response to citalopram in the patients. These preliminary results suggest that the cerebral metabolic response to citalopram may be a useful marker of the pathophysiology of serotonin function in geriatric depression.

[1]  D. Kupfer,et al.  Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. , 1999, The American journal of psychiatry.

[2]  C. Nemeroff,et al.  The serotonin transporter and depression , 1998, Depression and anxiety.

[3]  A. Beck,et al.  Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. , 1996, Journal of personality assessment.

[4]  S. Kapur,et al.  The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET , 1999, Psychopharmacology.

[5]  S. Kennedy,et al.  No effect of depression on [(15)O]H2O PET response to intravenous d-fenfluramine. , 1998, The American journal of psychiatry.

[6]  R. Parsey,et al.  Dopamine D2 receptor availability and amphetamine-induced dopamine release in unipolar depression , 2001, Biological Psychiatry.

[7]  Monte S. Buchsbaum,et al.  Effect of sertraline on regional metabolic rate in patients with affective disorder , 1997, Biological Psychiatry.

[8]  D. Overstreet,et al.  The role of acetylcholine mechanisms in mood disorders , 1995 .

[9]  Vijay Dhawan,et al.  Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects , 2002, Synapse.

[10]  D. Kupfer,et al.  Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging , 1998, Neuropsychopharmacology.

[11]  J John Mann,et al.  Role of the Serotonergic System in the Pathogenesis of Major Depression and Suicidal Behavior , 1999, Neuropsychopharmacology.

[12]  J. Mann,et al.  Blunted Serotonergic Responsivity in Depressed Inpatients , 1995, Neuropsychopharmacology.

[13]  P. Tariot,et al.  The effects of acute scopolamine in geriatric depression. , 1988, Archives of general psychiatry.

[14]  D. Kupfer,et al.  How common is resistance to treatment in recurrent, nonpsychotic geriatric depression? , 1998, The American journal of psychiatry.

[15]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[16]  S. Kapur,et al.  Role of the dopaminergic system in depression , 1992, Biological Psychiatry.

[17]  M S Buchsbaum,et al.  Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. , 1999, The American journal of psychiatry.

[18]  M. Mintun,et al.  Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. , 1996, The American journal of psychiatry.

[19]  P. Jerabek,et al.  Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response , 2000, Biological Psychiatry.

[20]  J A Yesavage,et al.  Geriatric Depression Scale. , 1988, Psychopharmacology bulletin.

[21]  I. Katz,et al.  The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. , 2001, Postgraduate medicine.

[22]  David Eidelberg,et al.  Quantitative Brain PET. Comparison of 2D and 3D Acquisitions on the GE Advance Scanner. , 1998, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[23]  V. Dhawan,et al.  Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve. , 1993, Radiology.

[24]  Gwenn S. Smith,et al.  Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[25]  J R Moeller,et al.  Regional cerebral blood flow in mood disorders, V.: Effects of antidepressant medication in late-life depression. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[26]  J. Seibyl,et al.  Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. , 2000, The American journal of psychiatry.

[27]  M. Thase,et al.  Fenfluramine challenge test as a predictor of outcome in major depression. , 1993, Psychopharmacology bulletin.

[28]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[29]  Daniel J Buysse,et al.  Temporal profiles of the course of depression during treatment. Predictors of pathways toward recovery in the elderly. , 1997, Archives of general psychiatry.

[30]  M. Schindl,et al.  The citalopram challenge test in patients with major depression and in healthy controls , 1999, Psychiatry Research.

[31]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.